Sabby entities disclose 9.9% Oragenics (OGEN) stake in Schedule 13G
Rhea-AI Filing Summary
Oragenics, Inc. received a Schedule 13G filing showing that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz together report beneficial ownership of 412,654 shares of Oragenics common stock. This position represents 9.9% of the outstanding common shares as of the filing. The reporting persons state they have shared voting and dispositive power over all 412,654 shares and no sole voting or dispositive power. They also certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Oragenics, but instead are held on a passive basis consistent with a Schedule 13G filing.
Positive
- None.
Negative
- None.
Insights
Sabby reports a passive 9.9% stake in Oragenics.
The filing shows Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz jointly reporting beneficial ownership of 412,654 Oragenics common shares, or
The use of a Schedule 13G and the certification language indicate the position is not intended to change or influence control of Oragenics. This makes the disclosure informational rather than strategic. Actual impact on trading or governance will depend on how this 9.9% holder chooses to vote and manage the position over time.
FAQ
What stake in Oragenics (OGEN) is reported in this Schedule 13G?
Who are the reporting persons in the Oragenics (OGEN) Schedule 13G?
Do the Oragenics (OGEN) Schedule 13G filers have voting and dispositive power over the shares?
Is the 9.9% Oragenics (OGEN) position reported as a passive investment?
What class of securities is covered by this Oragenics (OGEN) Schedule 13G?
When did the ownership level in this Oragenics (OGEN) Schedule 13G become reportable?